Search

Author/Creator Mookerjee, Bijoyesh

1. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Issue 4 (30th October 2013)

Authors:
Verstovsek, Srdan; Passamonti, Francesco; Rambaldi, Alessandro; Barosi, Giovanni; Rosen, Peter J.; Rumi, Elisa; Gattoni, Elisabetta; Pieri, Lisa; Guglielmelli, Paola; Elena, Chiara; He, Shui; Contel, Nancy; Mookerjee, Bijoyesh; Sandor, Victor; Cazzola, Mario; Kantarjian, Hagop M.; Barbui, Tiziano...
Journal:
Cancer
Issue:
Volume 120:Issue 4(2014)
Page Start:
513
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Issue 4 (30th October 2013)

Authors:
Verstovsek, Srdan; Passamonti, Francesco; Rambaldi, Alessandro; Barosi, Giovanni; Rosen, Peter J.; Rumi, Elisa; Gattoni, Elisabetta; Pieri, Lisa; Guglielmelli, Paola; Elena, Chiara; He, Shui; Contel, Nancy; Mookerjee, Bijoyesh; Sandor, Victor; Cazzola, Mario; Kantarjian, Hagop M.; Barbui, Tiziano...
Journal:
Cancer
Issue:
Volume 120:Issue 4(2014)
Page Start:
513
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Issue 13 (October 2015)

Authors:
Grob, Jean Jacques; Amonkar, Mayur M; Karaszewska, Boguslawa; Schachter, Jacob; Dummer, Reinhard; Mackiewicz, Andrzej; Stroyakovskiy, Daniil; Drucis, Kamil; Grange, Florent; Chiarion-Sileni, Vanna; Rutkowski, Piotr; Lichinitser, Mikhail; Levchenko, Evgeny; Wolter, Pascal; Hauschild, Axel; Long, G...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 13(2015)
Page Start:
1389
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Issue 9992 (1st August 2015)

Authors:
Long, Georgina V; Stroyakovskiy, Daniil; Gogas, Helen; Levchenko, Evgeny; de Braud, Filippo; Larkin, James; Garbe, Claus; Jouary, Thomas; Hauschild, Axel; Grob, Jean-Jacques; Chiarion-Sileni, Vanna; Lebbe, Celeste; Mandalà, Mario; Millward, Michael; Arance, Ana; Bondarenko, Igor; Haanen, John B A...
Journal:
Lancet
Issue:
Volume 386:Issue 9992(2015)
Page Start:
444
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Issue 9992 (1st August 2015)

Authors:
Long, Georgina V; Stroyakovskiy, Daniil; Gogas, Helen; Levchenko, Evgeny; de Braud, Filippo; Larkin, James; Garbe, Claus; Jouary, Thomas; Hauschild, Axel; Grob, Jean-Jacques; Chiarion-Sileni, Vanna; Lebbe, Celeste; Mandalà, Mario; Millward, Michael; Arance, Ana; Bondarenko, Igor; Haanen, John B A...
Journal:
Lancet
Issue:
Volume 386:Issue 9992(2015)
Page Start:
444
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. Issue 5 (May 2016)

Authors:
Planchard, David; Kim, Tae Min; Mazieres, Julien; Quoix, Elisabeth; Riely, Gregory; Barlesi, Fabrice; Souquet, Pierre-Jean; Smit, Egbert F; Groen, Harry J M; Kelly, Ronan J; Cho, B C; Socinski, Mark A; Pandite, Lini; Nase, Christine; Ma, Bo; D'Amelio, Anthony; Mookerjee, Bijoyesh; Curtis, C Marti...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 5(2016:May)
Page Start:
642
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Issue 7 (July 2017)

Authors:
Davies, Michael A; Saiag, Philippe; Robert, Caroline; Grob, Jean-Jacques; Flaherty, Keith T; Arance, Ana; Chiarion-Sileni, Vanna; Thomas, Luc; Lesimple, Thierry; Mortier, Laurent; Moschos, Stergios J; Hogg, David; Márquez-Rodas, Iván; Del Vecchio, Michele; Lebbé, Céleste; Meyer, Nicolas; Zhang, Y...
Journal:
Lancet oncology
Issue:
Volume 18:Issue 7(2017:Jul.)
Page Start:
863
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Issue 7 (July 2016)

Authors:
Planchard, David; Besse, Benjamin; Groen, Harry J M; Souquet, Pierre-Jean; Quoix, Elisabeth; Baik, Christina S; Barlesi, Fabrice; Kim, Tae Min; Mazieres, Julien; Novello, Silvia; Rigas, James R; Upalawanna, Allison; D'Amelio, Anthony M; Zhang, Pingkuan; Mookerjee, Bijoyesh; Johnson, Bruce E
Journal:
Lancet oncology
Issue:
Volume 17:Issue 7(2016:Jul.)
Page Start:
984
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Issue 10 (October 2017)

Authors:
Planchard, David; Smit, Egbert F; Groen, Harry J M; Mazieres, Julien; Besse, Benjamin; Helland, Åslaug; Giannone, Vanessa; D'Amelio, Anthony M; Zhang, Pingkuan; Mookerjee, Bijoyesh; Johnson, Bruce E
Journal:
Lancet oncology
Issue:
Volume 18:Issue 10(2017:Oct.)
Page Start:
1307
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600–mutant tumours. (23rd January 2018)

Authors:
Nebot, Noelia; Arkenau, Hendrik‐Tobias; Infante, Jeffrey R.; Chandler, Jason C.; Weickhardt, Andrew; Lickliter, Jason D.; Sarantopoulos, John; Gordon, Michael S.; Mak, Gabriel; St‐Pierre, Annie; Tang, Lihua; Mookerjee, Bijoyesh; Carson, Stanley W.; Hayes, Siobhan; Grossmann, Kenneth F.
Journal:
British journal of clinical pharmacology
Issue:
Volume 84:Number 4(2018:Oct.)
Page Start:
764
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗